1992-93 |
Biotechnology Transfer, Inc. is founded (from
a $50,000 loan from the Jim Rouse Entrepreneurial Fund in Howard
County, MD) with an initial product that was a natural human interleukin
2 T-cell growth factor used for research - ImmuKnow® (as we now know
it) was named “The Luminetics™ Assay for T-Cell Activation” |
1995-96 |
The Company receives a Small
Business Innovation Grant (SBIR) from the Department of the Army
to develop a test for the efficacy of a Q fever vaccine, which provides
the fundamental proof of principle for the ImmuKnow technology in
its current form |
1997 |
U.S. patent titled, “Methods for Measurement of
Lymphocyte Function” (US 5,773,232) is filed with the U.S. Patent & Trademark
Office |
1997 |
Dr. Judy Britz is named President
and CEO |
1998 |
First financing round opens |
1998 |
U.S. patent titled, “Methods
for Measurement of Lymphocyte Function” (US 6,630,316) is filed with
the U.S. Patent & Trademark Office (e.g., the Luminetics
Assay) |
1998 |
The Company changes its name to Cylex Incorporated® |
2000 |
Cylex raises $3.6 million
in first round financing |
2000 |
FDA meetings begin (about 5 employees) – Define
the 510-K path, design a clinical protocol and identify study sites |
2001 |
FDA submission for transplant
application |
2001 |
Cylex raises $2 million in interim financing |
2001 |
Cylex adds GMP manufacturing
capability |
2002 |
Cylex announces FDA clearance for Immune Cell
Function Assay, and the product name changes to ImmuKnow |
2002 |
Second round financing opens |
2003 |
U.S. patents titled, “Method for Monitoring the
Immune Response and Predicting Clinical Outcomes in Transplant Recipients”
(US 7,476,514 B2, US 7,169,571) are filed with the U.S. Patent & Trademark
Office |
2004 |
Cylex raises $6.4 million in
second round financing |
2004 |
ImmuKnow receives CE-marking in the EU |
2006 |
Third round financing opens |
2007 |
Cylex raises $20.5 million in third round financing |
2008 |
Brad L. Stewart is named President
and Douglas Brown is named Chief Financial Officer |
2008 |
Cylex receives ISO 13485:2003 and
9001:2000 quality certifications |
2009 |
Cylex expands its facility
from 7,100 to 11,850 square feet |
2009 |
Cylex President Brad L. Stewart is
named Chairman of the Board and CEO |
2010 |
Cylex receives new Class
One CPT code for ImmuKnow |
